What is the PERL study?

- Patients with Type 1 diabetes remain at risk for end-stage renal disease despite improvements in medicines that target blood pressure and glycemic control.

- The PERL study is a three-year, multi-center study evaluating the efficacy of the urate-lowering drug allopurinol, as compared to placebo, in reducing kidney function loss among subjects with T1D.

How can I participate in the study?

- The PERL study is being conducted at the Joslin Diabetes Center in Boston, MA, the University of Minnesota in St. Paul/Minneapolis, MN, University of Colorado Denver in Aurora, CO, University of Michigan in Ann Arbor, MI, Northwestern University in Chicago, IL, Albert Einstein College of Medicine in Bronx, NY, Mount Sinai Hospital in Toronto, Ontario, and the Steno Diabetes Center in Copenhagen, Denmark.

If you are interested in the study please call:

Daphne Adelman 312-908-9002 / Elaine Massaro 312-926-9628
Diane Larsen 312-503-2873

Perl Website: perl-study.org

Funding support from: